A Comparison of the Chronic Migraine Epidemiology & Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability (P1.167) (2016)

Objective: To compare the methods and results of the AMPP and CaMEO studies.
 Background: The AMPP and CaMEO studies longitudinally explored migraine epidemiology, demographic/socioeconomic characteristics, and patterns of care using different methods.
 Methods: This analysis used baseline AMPP (2005) and CaMEO data. Both studies enrolled respondents who met modified ICHD-3b migraine criteria using a validated questionnaire, stratified by episodic (EM: <15 headache days/month) or chronic migraine (CM: ≥15 headache days/month). Study outcomes included demographics, headache frequency, and headache-related disability (Migraine Disability Assessment [MIDAS]) among persons with EM and CM.
 Results: Methodologic differences included data collection (postal survey [AMPP] vs. web survey [CaMEO]), duration (annually over 6 years vs quarterly over 15 months), eligibility criteria (severe headache vs headache), response rate (77.1[percnt] vs 16.5[percnt]), and scope (CaMEO was designed to expand on AMPP). Demographic distribution was generally similar, indicating broad US population representation for migraine, with 6.6[percnt] (AMPP) and 8.8[percnt] (CaMEO) of respondents meeting the CM case definition. Respondents had similar median headache frequency (days/month) for CM in total and by sex (AMPP: male=21.7, female=20.0; CaMEO: male=20.0, female=20.0) and EM (AMPP: male=1.7, female=2.0; CaMEO: male=2.0, female=3.0). Median MIDAS score was substantially higher in both studies for CM (severe disability [Grade IV]; AMPP: male=33.0, female=45.0; CaMEO: male=32.0, female=38.0) than EM (little/mild disability [Grade I/II]; AMPP: male=3.0, female=6.0; CaMEO: male=4.0, female=7.0). Rates of moderate/severe disability (Grade III/IV) were substantially higher in both studies for CM (AMPP: male=66.9[percnt], female=78.9[percnt]; CaMEO: male=71.0[percnt], female=82.6[percnt]) than EM (AMPP: male=23.0[percnt], female=31.8[percnt]; CaMEO: male=26.7[percnt], female=37.9[percnt]). More female than male respondents experienced moderate/severe disability in both studies.
 Conclusions: AMPP and CaMEO were longitudinal cohort studies that used different methods, but yielded similar results for demographic features, headache frequency, and headache-related disability. Both studies found severe headache-related disability for CM vs EM in total samples and by sex.
 Support: Allergan. Disclosure: Dr. Buse has received personal compensation for activities with Allergan, Avanir, and Eli Lilly. Dr. Buse has received research support from Allergan and Avanir. Dr. Lipton has received personal compensation for activities with Allergan, American Headache Society, Autonomic Technologies, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Eli-Lilly, eNeura Therapeutics, Merck, Novartis, Pfizer, Teva, and V Dr. Adams has received personal compensation for activities with Allergan, Inc. as an employee. Dr. Fanning has received personal compensation for activities with Allergan, Inc., Endo Pharmaceuticals, GlaxoSmithKline, MAP Pharmaceuticals, Merck & Co., Inc., NuPathe, Novartis, and Ortho-McNeil. Dr. Reed has received personal compensation for activities with Allergan, Inc., Colucid, Endo Pharmaceuticals, GlaxoSmithKline, Merck & Co., Inc., NuPathe, Novartis, and Ortho-McNeil.